Connect your AI

Evommune EVMN Short- and long-term operating lease liabilities

Short- and long-term operating lease liabilities at other companies

Oruka Therapeutics, Inc.ORKA

-$125K-495%

Rumble, Inc.RUM

-$337.78K-40.4%

Mission Produce, Inc.AVO

-$2.8M-3.7%

The Baldwin Insurance Group, Inc.BWIN

-$4.74M-16.2%

NextNavNN

$77K-63.7%

Target HospitalityTH

-$2.3M-33.9%

Other financials

Income statement

Revenue$1.6M+3.5%

Gross profit$961.1K+10.9%

Operating income-$682.8K-2,027%

Net income-$7.0M-5,414%

EPS (diluted)-$0.36-1,700%

Balance sheet

Cash & equivalents$1.1M+401%

Total debt$2.0M—

Total equity-$4.5M-3,048%

Total assets$7.2M—

Cash flow

Operating cash flow-$424.6K-341%

CapEx$1.0-99.8%

Free cash flow-$2.7M-4,996%

Valuation

Market cap$848.59M+39.5%

Enterprise value$849.52M—

P/S127.3×—

Profitability

Gross margin53.7%—

Operating margin-30.7%—

Net margin-90.1%—

Returns & leverage

Return on equity275.7%—

Debt / equity1.4×—

Current ratio1.2×—

Where this comes from

Reported directly by Evommune in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Evommune ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evommune 's short- and long-term operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Evommune 's short- and long-term operating lease liabilities?: Evommune (EVMN) reported short- and long-term operating lease liabilities of -$90.99K in Q1 2026.
What does short- and long-term operating lease liabilities mean?: Represents the net change in the present value of future lease payments for operating assets like office or laboratory space. This metric reflects the company's long-term commitment to leased facilities and its impact on the balance sheet. Changes indicate new lease agreements or the amortization of existing lease obligations.